Indeed, PARP1 inhibition could lead to immunogenic neoantigen accumulation, presented on the surface of dying CML cells, recognized by the immune system to improve immune recognition of cells otherwise poorly immunogenic. The gene discussed is PARP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.